{"protocolSection":{"identificationModule":{"nctId":"NCT00952419","orgStudyIdInfo":{"id":"FUF15"},"secondaryIdInfos":[{"id":"UTN: U1111-1111-4713"}],"organization":{"fullName":"Sanofi","class":"INDUSTRY"},"briefTitle":"A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years","officialTitle":"Immunogenicity and Safety of Multiple Formulations of an A/H1N1 Pandemic Vaccine in Healthy Subjects Aged 6 Months to 9 Years"},"statusModule":{"statusVerifiedDate":"2016-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2009-08"},"primaryCompletionDateStruct":{"date":"2010-03","type":"ACTUAL"},"completionDateStruct":{"date":"2010-06","type":"ACTUAL"},"studyFirstSubmitDate":"2009-08-03","studyFirstSubmitQcDate":"2009-08-04","studyFirstPostDateStruct":{"date":"2009-08-06","type":"ESTIMATED"},"resultsFirstSubmitDate":"2011-06-08","resultsFirstSubmitQcDate":"2011-06-08","resultsFirstPostDateStruct":{"date":"2011-07-11","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-04-12","lastUpdatePostDateStruct":{"date":"2016-04-14","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Sanofi Pasteur, a Sanofi Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine in toddlers and children.\n\nPrimary Objectives:\n\n* To describe the immunogenicity of the candidate vaccines after each injection.\n* To describe the safety of the candidate vaccines after each injection.","detailedDescription":"Participants will receive two injections of their randomized vaccine on Day 0 and Day 21, respectively."},"conditionsModule":{"conditions":["Influenza","Swine-origin A/H1N1 Influenza"],"keywords":["Influenza","Pandemic Flu","Swine-origin A/H1N1 Influenza","Children"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":474,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"A/H1N1 Vaccine Group 1","type":"EXPERIMENTAL","description":"Participants will receive A/H1N1 vaccine formulation 1","interventionNames":["Biological: Monovalent Subvirion A/H1N1 Influenza vaccine"]},{"label":"A/H1N1 Vaccine Group 2","type":"EXPERIMENTAL","description":"Participants will receive A/H1N1 vaccine formulation 2","interventionNames":["Biological: Monovalent Subvirion A/H1N1 Influenza vaccine"]},{"label":"Placebo Group","type":"PLACEBO_COMPARATOR","description":"Participants will receive a placebo vaccine","interventionNames":["Biological: Normal saline solution (placebo)"]}],"interventions":[{"type":"BIOLOGICAL","name":"Monovalent Subvirion A/H1N1 Influenza vaccine","description":"0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on Day 0 and Day 21 (6 months to 35 Months)","armGroupLabels":["A/H1N1 Vaccine Group 1"]},{"type":"BIOLOGICAL","name":"Monovalent Subvirion A/H1N1 Influenza vaccine","description":"0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on day 0 and Day 21 (6 months to 35 Months)","armGroupLabels":["A/H1N1 Vaccine Group 2"]},{"type":"BIOLOGICAL","name":"Normal saline solution (placebo)","description":"0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on day 0 and Day 21 (6 months to 35 Months)","armGroupLabels":["Placebo Group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Antibody Titers ≥ 10 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age 6 to 35 Months","description":"Pre- and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.","timeFrame":"Pre-vaccination (Day 0) and 21 days post-vaccination"},{"measure":"Number of Participants With Antibody Titers ≥ 40 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age 6 to 35 Months","description":"Seroprotection: Antibody titer of ≥ 40 1/dil. Antibody titers were determined by the hemagglutination inhibition (HAI) test.","timeFrame":"Pre-vaccination (Day 0) and Day 21 post-vaccination"},{"measure":"Geometric Mean Titers (GMT) of Antibodies Against A/California (H1N1 Vaccine) Strain - Age 6 to 35 Months","description":"Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.","timeFrame":"Pre-vaccination (Day 0) and 21 days post-vaccination"},{"measure":"Number of Participants With Antibody Titers ≥ 10 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age 3 to 9 Years","description":"Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.","timeFrame":"Pre-vaccination (Day 0) and 21 days post-vaccination"},{"measure":"Number of Participants With Antibody Titers ≥ 40 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age 3 to 9 Years","description":"Seroprotection: Antibody titer ≥ 40 1/dil. Antibody titers were determined by the hemagglutination inhibition (HAI) test.","timeFrame":"Pre-vaccination (Day 0) and Day 21 post-vaccination"},{"measure":"Geometric Mean Titers (GMT) of Antibodies Against A/California (H1N1 Vaccine) Strain - Age 3 to 9 Years","description":"Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.","timeFrame":"Pre-vaccination (Day 0) and Day 21 post-vaccination"},{"measure":"Number of Participants With At Least One Solicited Injection Site or Systemic Reaction Following Vaccination - Age 6 to 23 Months","description":"Solicited Injection Site Reactions: Tenderness, erythema (redness), swelling, induration (hardening), ecchymosis (bruising). Solicited systemic reactions: Fever (temperature), vomiting, crying abnormal, drowsiness, appetite lost, irritability.","timeFrame":"Days 0 to 7 post-vaccination"},{"measure":"Number of Participants With At Least One Solicited Injection Site or Systemic Reaction Following Vaccination - Age 24 to 35 Months","description":"Solicited Injection Site Reactions: Pain, erythema (redness), swelling, induration (hardening), ecchymosis (bruising). Solicited systemic reactions: Fever (temperature), headache, malaise (feeling unwell), myalgia (muscle aches and pains), shivering.","timeFrame":"Days 0 to 7 post-vaccination"},{"measure":"Number of Participants With At Least One Solicited Injection Site or Systemic Reaction Following Vaccination - Age 3 to 9 Years","description":"Solicited Injection Site Reactions: Pain, erythema (redness), swelling, induration (hardening), ecchymosis (bruising). Solicited systemic reactions: Fever (temperature), headache, malaise (feeling unwell), myalgia (muscle aches and pains), shivering.","timeFrame":"Days 0 to 7 post vaccination"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria :\n\nAll subjects:\n\n* Provision of Informed Consent Form signed by the subject's parent(s)/legal representative (and by an independent witness if required by local regulations). In addition, provision of Assent Form signed by subjects aged 7 to 9 years\n* Subject and parent/guardian are able to attend all scheduled visits and to comply with all trial procedures\n\nSubjects aged 3 to 9 years:\n\n* Healthy children aged 3 to 9 years on the day of inclusion\n\nSubjects aged 6 to 35 months:\n\n* Healthy infants and toddlers aged 6 to 35 months on the day of inclusion\n* Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg\n\nExclusion Criteria :\n\n* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination\n* Planned participation in another clinical trial during the present trial period\n* Receipt of any vaccine in the 4 weeks preceding the trial vaccination\n* Planned receipt of any vaccine prior to the Day 42 blood sample\n* Receipt of blood or blood-derived products in the past 3 months which might interfere with the assessment of immune response\n* Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)\n* Self-reported seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B surface antigen, or Hepatitis C\n* Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances\n* Self reported thrombocytopenia contraindicating intramuscular (IM) vaccination\n* Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion contraindicating IM vaccination\n* Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily\n* Chronic illness that in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion\n* Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.\n* Any confirmed case of influenza (including swine-origin A/H1N1 Influenza) since March 2009\n* Personal or family history of Guillain-Barré syndrome\n* Active neoplastic disease or a history of any hematologic malignancy\n* Known seizure/epilepsy history and/or taking anti-seizure medication\n* Receipt of psychiatric drugs. Subjects receiving a single antidepressant drug and stable for at least 3 months prior to enrollment, without decompensating symptoms will be allowed to enroll in the study\n* Febrile illness (temperature ≥ 100.4°F \\[≥ 38.0°C\\]) or moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Months","maximumAge":"9 Years","stdAges":["CHILD"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Monitor","affiliation":"Sanofi Pasteur Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Miami Beach","state":"Florida","zip":"33141","country":"United States","geoPoint":{"lat":25.79065,"lon":-80.13005}},{"city":"Marietta","state":"Georgia","zip":"30062","country":"United States","geoPoint":{"lat":33.9526,"lon":-84.54993}},{"city":"Woodstock","state":"Georgia","zip":"30189","country":"United States","geoPoint":{"lat":34.10149,"lon":-84.51938}},{"city":"Crestview Hills","state":"Kentucky","zip":"41017","country":"United States","geoPoint":{"lat":39.02728,"lon":-84.58494}},{"city":"Louisville","state":"Kentucky","zip":"40291","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"city":"Maddisonville","state":"Kentucky","zip":"42431","country":"United States"},{"city":"Metairie","state":"Louisiana","zip":"70006","country":"United States","geoPoint":{"lat":29.98409,"lon":-90.15285}},{"city":"Las Vegas","state":"Nevada","zip":"89104","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"city":"Rochester","state":"New York","zip":"14609","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"city":"Hermitage","state":"Pennsylvania","zip":"16148","country":"United States","geoPoint":{"lat":41.23339,"lon":-80.44868}},{"city":"Pittsburgh","state":"Pennsylvania","zip":"15237","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"city":"Pittsburgh","state":"Pennsylvania","zip":"15241","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"city":"Cranston","state":"Rhode Island","zip":"O2920","country":"United States","geoPoint":{"lat":41.77982,"lon":-71.43728}},{"city":"Barnwell","state":"South Carolina","zip":"29812","country":"United States","geoPoint":{"lat":33.24487,"lon":-81.35872}},{"city":"Austin","state":"Texas","zip":"78705","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"city":"Fort Worth","state":"Texas","zip":"76135","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"city":"San Angelo","state":"Texas","zip":"76904","country":"United States","geoPoint":{"lat":31.46377,"lon":-100.43704}},{"city":"Orem","state":"Utah","zip":"84057","country":"United States","geoPoint":{"lat":40.2969,"lon":-111.69465}},{"city":"South Jordan","state":"Utah","zip":"84095","country":"United States","geoPoint":{"lat":40.56217,"lon":-111.92966}},{"city":"Springville","state":"Utah","zip":"84663","country":"United States","geoPoint":{"lat":40.16523,"lon":-111.61075}}]},"referencesModule":{"references":[{"pmid":"21219979","type":"RESULT","citation":"Plennevaux E, Blatter M, Cornish MJ, Go K, Kirby D, Wali M, Reeves-Hoche MK, Denis M. Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial. Vaccine. 2011 Feb 11;29(8):1569-75. doi: 10.1016/j.vaccine.2010.12.116. Epub 2011 Jan 8."},{"pmid":"20018365","type":"DERIVED","citation":"Plennevaux E, Sheldon E, Blatter M, Reeves-Hoche MK, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet. 2010 Jan 2;375(9708):41-8. doi: 10.1016/S0140-6736(09)62026-2. Epub 2009 Dec 15."}],"seeAlsoLinks":[{"label":"Related Info","url":"http://www.sanofipasteur.com"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 474 participants who met the inclusion and exclusion criteria were enrolled, vaccinated, and included in data analysis.","recruitmentDetails":"Participants were enrolled from 06 August 2009 to 13 August 2009 at 19 US clinical centers.","groups":[{"id":"FG000","title":"A/H1N1 Vaccine Group 1","description":"Participants who received a dose of 7.5 μg hemagglutinin intramuscularly on Day 1 and Day 21, respectively."},{"id":"FG001","title":"A/H1N1 Vaccine Group 2","description":"Participants who received a dose of 15 μg hemagglutinin intramuscularly on Day 1 and Day 21, respectively."},{"id":"FG002","title":"Placebo Group","description":"Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"215"},{"groupId":"FG001","numSubjects":"208"},{"groupId":"FG002","numSubjects":"51"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"209"},{"groupId":"FG001","numSubjects":"198"},{"groupId":"FG002","numSubjects":"51"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"A/H1N1 Vaccine Group 1","description":"Participants who received a dose of 7.5 μg hemagglutinin intramuscularly on Day 1 and Day 21, respectively."},{"id":"BG001","title":"A/H1N1 Vaccine Group 2","description":"Participants who received a dose of 15 μg hemagglutinin intramuscularly on Day 1 and Day 21, respectively."},{"id":"BG002","title":"Placebo Group","description":"Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"215"},{"groupId":"BG001","value":"208"},{"groupId":"BG002","value":"51"},{"groupId":"BG003","value":"474"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"215"},{"groupId":"BG001","value":"208"},{"groupId":"BG002","value":"51"},{"groupId":"BG003","value":"474"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4.1","spread":"2.8"},{"groupId":"BG001","value":"4.3","spread":"2.8"},{"groupId":"BG002","value":"3.7","spread":"2.7"},{"groupId":"BG003","value":"4.2","spread":"2.8"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"111"},{"groupId":"BG001","value":"99"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"234"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"104"},{"groupId":"BG001","value":"109"},{"groupId":"BG002","value":"27"},{"groupId":"BG003","value":"240"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"215"},{"groupId":"BG001","value":"208"},{"groupId":"BG002","value":"51"},{"groupId":"BG003","value":"474"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Antibody Titers ≥ 10 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age 6 to 35 Months","description":"Pre- and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.","populationDescription":"Pre- and post-vaccination antibody titers were assessed in the per-protocol population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Pre-vaccination (Day 0) and 21 days post-vaccination","groups":[{"id":"OG000","title":"A/H1N1 Vaccine Group 1","description":"Participants who received a dose of 7.5 μg hemagglutinin intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG001","title":"A/H1N1 Vaccine Group 2","description":"Participants who received a dose of 15 μg hemagglutinin intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG002","title":"Placebo Group","description":"Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"23"}]}],"classes":[{"title":"Pre-Vaccination 1 (Day 0) Titers at ≥ 10 1/dil","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]},{"title":"Post-Vaccination 1 (Day 21) Titers at ≥ 10 1/dil","categories":[{"measurements":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"79"},{"groupId":"OG002","value":"0"}]}]},{"title":"Post-Vaccination 2 (Day 42) Titers at ≥ 10 1/dil","categories":[{"measurements":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"1"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Antibody Titers ≥ 40 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age 6 to 35 Months","description":"Seroprotection: Antibody titer of ≥ 40 1/dil. Antibody titers were determined by the hemagglutination inhibition (HAI) test.","populationDescription":"Antibody titers were assessed in the per-protocol population.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Pre-vaccination (Day 0) and Day 21 post-vaccination","groups":[{"id":"OG000","title":"A/H1N1 Vaccine Group 1","description":"Participants who received a dose of 7.5 μg hemagglutinin intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG001","title":"A/H1N1 Vaccine Group 2","description":"Participants who received a dose of 15 μg hemagglutinin intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG002","title":"Placebo Group","description":"Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"23"}]}],"classes":[{"title":"Pre-Vaccination 1 (Day 0) Titers at ≥ 40 1/dil","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]},{"title":"Post-Vaccination 1 (Day 21) Titers at ≥ 40 1/dil","categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"0"}]}]},{"title":"Post-Vaccination 2 (Day 42) Titers at ≥ 40 1/dil","categories":[{"measurements":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"86"},{"groupId":"OG002","value":"1"}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMT) of Antibodies Against A/California (H1N1 Vaccine) Strain - Age 6 to 35 Months","description":"Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.","populationDescription":"Antibody titers were assessed in the per-protocol population.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers","timeFrame":"Pre-vaccination (Day 0) and 21 days post-vaccination","groups":[{"id":"OG000","title":"A/H1N1 Vaccine Group 1","description":"Participants who received a dose of 7.5 μg hemagglutinin intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG001","title":"A/H1N1 Vaccine Group 2","description":"Participants who received a dose of 15 μg hemagglutinin intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG002","title":"Placebo Group","description":"Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"23"}]}],"classes":[{"title":"Pre-Vaccination 1 (Day 0) GMT","categories":[{"measurements":[{"groupId":"OG000","value":"5.99","lowerLimit":"5.10","upperLimit":"7.04"},{"groupId":"OG001","value":"5.48","lowerLimit":"4.84","upperLimit":"6.20"},{"groupId":"OG002","value":"5.00","lowerLimit":"5.00","upperLimit":"5.00"}]}]},{"title":"Post-Vaccination 1 (Day 21) GMT","categories":[{"measurements":[{"groupId":"OG000","value":"33.3","lowerLimit":"23.8","upperLimit":"46.5"},{"groupId":"OG001","value":"45.1","lowerLimit":"32.8","upperLimit":"62.0"},{"groupId":"OG002","value":"5.08","lowerLimit":"4.92","upperLimit":"5.24"}]}]},{"title":"Post-Vaccination 2 (Day 42) GMT","categories":[{"measurements":[{"groupId":"OG000","value":"368","lowerLimit":"271","upperLimit":"500"},{"groupId":"OG001","value":"586","lowerLimit":"451","upperLimit":"763"},{"groupId":"OG002","value":"5.64","lowerLimit":"4.39","upperLimit":"7.24"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Antibody Titers ≥ 10 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age 3 to 9 Years","description":"Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.","populationDescription":"Pre- and post-vaccination antibody titers were assessed in the per-protocol population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Pre-vaccination (Day 0) and 21 days post-vaccination","groups":[{"id":"OG000","title":"A/H1N1 Vaccine Group 1","description":"Participants who received a dose of 7.5 μg hemagglutinin intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG001","title":"A/H1N1 Vaccine Group 2","description":"Participants who received a dose of 15 μg hemagglutinin intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG002","title":"Placebo Group","description":"Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"91"},{"groupId":"OG002","value":"24"}]}],"classes":[{"title":"Pre-Vaccination 1(Day 0) Titers at ≥ 10 1/dil","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"7"}]}]},{"title":"Post-Vaccination 1 (Day 21) Titers at ≥ 10 1/dil","categories":[{"measurements":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"88"},{"groupId":"OG002","value":"8"}]}]},{"title":"Post-Vaccination 2 (Day 42) Titers at ≥ 10 1/dil","categories":[{"measurements":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"91"},{"groupId":"OG002","value":"8"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Antibody Titers ≥ 40 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age 3 to 9 Years","description":"Seroprotection: Antibody titer ≥ 40 1/dil. Antibody titers were determined by the hemagglutination inhibition (HAI) test.","populationDescription":"Pre- and post-vaccination antibody titers were assessed in the per-protocol population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Pre-vaccination (Day 0) and Day 21 post-vaccination","groups":[{"id":"OG000","title":"A/H1N1 Vaccine Group 1","description":"Participants who received a dose of 7.5 μg hemagglutinin intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG001","title":"A/H1N1 Vaccine Group 2","description":"Participants who received a dose of 15 μg hemagglutinin intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG002","title":"Placebo Group","description":"Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"91"},{"groupId":"OG002","value":"24"}]}],"classes":[{"title":"Pre-Vaccination 1 (Day 0) Titers at ≥ 40 1/dil","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"5"}]}]},{"title":"Post-Vaccination 1 (Day 21) Titers at ≥ 40 1/dil","categories":[{"measurements":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"5"}]}]},{"title":"Post-Vaccination 2 (Day 42) Titers at ≥ 40 1/dil","categories":[{"measurements":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"90"},{"groupId":"OG002","value":"6"}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMT) of Antibodies Against A/California (H1N1 Vaccine) Strain - Age 3 to 9 Years","description":"Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.","populationDescription":"Antibody titers were assessed in the per-protocol population.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers","timeFrame":"Pre-vaccination (Day 0) and Day 21 post-vaccination","groups":[{"id":"OG000","title":"A/H1N1 Vaccine Group 1","description":"Participants who received a dose of 7.5 μg hemagglutinin intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG001","title":"A/H1N1 Vaccine Group 2","description":"Participants who received a dose of 15 μg hemagglutinin intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG002","title":"Placebo Group","description":"Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"91"},{"groupId":"OG002","value":"24"}]}],"classes":[{"title":"Pre-Vaccination 1 (Day 0) GMT","categories":[{"measurements":[{"groupId":"OG000","value":"6.01","lowerLimit":"5.20","upperLimit":"6.94"},{"groupId":"OG001","value":"5.54","lowerLimit":"5.03","upperLimit":"6.10"},{"groupId":"OG002","value":"11.9","lowerLimit":"6.17","upperLimit":"22.9"}]}]},{"title":"Post-Vaccination 1 (Day 21) GMT","categories":[{"measurements":[{"groupId":"OG000","value":"74.8","lowerLimit":"53.5","upperLimit":"105"},{"groupId":"OG001","value":"104","lowerLimit":"77.1","upperLimit":"140"},{"groupId":"OG002","value":"12.1","lowerLimit":"6.53","upperLimit":"22.3"}]}]},{"title":"Post-Vaccination 2 (Day 42) GMT","categories":[{"measurements":[{"groupId":"OG000","value":"459","lowerLimit":"348","upperLimit":"605"},{"groupId":"OG001","value":"586","lowerLimit":"454","upperLimit":"756"},{"groupId":"OG002","value":"14.3","lowerLimit":"7.02","upperLimit":"29.3"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With At Least One Solicited Injection Site or Systemic Reaction Following Vaccination - Age 6 to 23 Months","description":"Solicited Injection Site Reactions: Tenderness, erythema (redness), swelling, induration (hardening), ecchymosis (bruising). Solicited systemic reactions: Fever (temperature), vomiting, crying abnormal, drowsiness, appetite lost, irritability.","populationDescription":"Safety analysis was on all enrolled and vaccinated participants with available reaction data, intent-to-treat population.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Days 0 to 7 post-vaccination","groups":[{"id":"OG000","title":"A/H1N1 Vaccine Group 1","description":"Participants who received a dose of 7.5 μg hemagglutinin intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG001","title":"A/H1N1 Vaccine Group 2","description":"Participants who received a dose of 15 μg hemagglutinin intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG002","title":"Placebo Group","description":"Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"18"}]}],"classes":[{"title":"Any Solicited Injection Site Reaction - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"11"}]}]},{"title":"Grade (Grd) 3 Injection Site Reaction - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Tenderness - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"5"}]}]},{"title":"Any Tenderness - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"7"}]}]},{"title":"Any Tenderness - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"10"}]}]},{"title":"Grd 3 Tenderness-Crying or movement less, Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Erythema - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"}]}]},{"title":"Any Erythema - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"2"}]}]},{"title":"Any Erythema - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"3"}]}]},{"title":"Grade 3 Erythema (≥ 5 cm) Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Swelling - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Swelling - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"}]}]},{"title":"Any Swelling - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"}]}]},{"title":"Grade 3 Swelling (≥ 5 cm) Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Induration - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"}]}]},{"title":"Any Induration - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Induration - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"}]}]},{"title":"Grade 3 Induration (≥ 5 cm) Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Ecchymosis - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Ecchymosis - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Ecchymosis - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"}]}]},{"title":"Grade 3 Ecchymosis (≥ 5 cm) Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Solicited Systemic Reaction - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"11"}]}]},{"title":"Any Grade 3 Solicited Systemic Reaction - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Fever - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Fever - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"}]}]},{"title":"Any Fever - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"}]}]},{"title":"Grade 3 Fever ( ≥102.1 ºF or ≥39.0 ºC) - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Vomiting - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Vomiting - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Vomiting - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"}]}]},{"title":"Grade 3 Vomiting (> 6 episodes/24 hr) Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Crying Abnormal - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"5"}]}]},{"title":"Any Crying Abnormal - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"4"}]}]},{"title":"Any Crying Abnormal - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"7"}]}]},{"title":"Grade 3 Crying Abnormal (>3 hr) Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Drowsiness - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"3"}]}]},{"title":"Any Drowsiness - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"2"}]}]},{"title":"Any Drowsiness - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"3"}]}]},{"title":"Grade 3 Drowsiness (Sleeps most of time) Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Appetite Lost - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"3"}]}]},{"title":"Any Appetite Lost - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"3"}]}]},{"title":"Any Appetite Lost - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"4"}]}]},{"title":"Grd 3 Appetite Lost (Refused 3 meals) Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Irritability - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"7"}]}]},{"title":"Any Irritability - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"6"}]}]},{"title":"Any Irritability - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"9"}]}]},{"title":"Grade 3 Irritability (Inconsolable) Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With At Least One Solicited Injection Site or Systemic Reaction Following Vaccination - Age 24 to 35 Months","description":"Solicited Injection Site Reactions: Pain, erythema (redness), swelling, induration (hardening), ecchymosis (bruising). Solicited systemic reactions: Fever (temperature), headache, malaise (feeling unwell), myalgia (muscle aches and pains), shivering.","populationDescription":"Safety analysis was on all enrolled and vaccinated participants with available reaction data, intent-to-treat population.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Days 0 to 7 post-vaccination","groups":[{"id":"OG000","title":"A/H1N1 Vaccine Group 1","description":"Participants who received a dose of 7.5 μg hemagglutinin intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG001","title":"A/H1N1 Vaccine Group 2","description":"Participants who received a dose of 15 μg hemagglutinin intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG002","title":"Placebo Group","description":"Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"8"}]}],"classes":[{"title":"Any Solicited Injection Site Reaction - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"5"}]}]},{"title":"Grade (Grd) 3 Injection Site Reaction - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Pain - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"3"}]}]},{"title":"Any Pain - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"2"}]}]},{"title":"Any Pain - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"3"}]}]},{"title":"Grade 3 Pain (Incapacitating) - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Erythema - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"3"}]}]},{"title":"Any Erythema - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"}]}]},{"title":"Any Erythema - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"3"}]}]},{"title":"Grade 3 Erythema (≥ 5 cm) Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Swelling - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Swelling - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Swelling - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"}]}]},{"title":"Grade 3 Swelling (≥ 5 cm) Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Induration - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"}]}]},{"title":"Any Induration - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"}]}]},{"title":"Any Induration - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"}]}]},{"title":"Grade 3 Induration (≥ 5 cm) Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Ecchymosis - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"}]}]},{"title":"Any Ecchymosis - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Ecchymosis - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"2"}]}]},{"title":"Grade 3 Ecchymosis (≥ 5 cm) Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Solicited Systemic Reaction - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"3"}]}]},{"title":"Any Grade 3 Solicited Systemic Reaction - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}]}]},{"title":"Any Fever - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}]},{"title":"Any Fever - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Fever - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}]}]},{"title":"Grade 3 Fever (≥ 102.1 ºF or ≥ 39.0 ºC) -Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}]},{"title":"Any Headache - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}]},{"title":"Any Headache - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}]},{"title":"Any Headache - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}]}]},{"title":"Grd 3 Headache (Prevents daily activity) Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Malaise - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"}]}]},{"title":"Any Malaise - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"2"}]}]},{"title":"Any Malaise - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"3"}]}]},{"title":"Grd 3 Malaise (Prevents daily activity) Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Myalgia - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"}]}]},{"title":"Any Myalgia - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}]}]},{"title":"Any Myalgia - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"2"}]}]},{"title":"Grd 3 Myalgia (Prevents Daily Activity) Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Shivering - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Shivering - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Shivering - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Grade 3 Shivering (Prevents activity) - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With At Least One Solicited Injection Site or Systemic Reaction Following Vaccination - Age 3 to 9 Years","description":"Solicited Injection Site Reactions: Pain, erythema (redness), swelling, induration (hardening), ecchymosis (bruising). Solicited systemic reactions: Fever (temperature), headache, malaise (feeling unwell), myalgia (muscle aches and pains), shivering.","populationDescription":"Safety analysis was on all enrolled and vaccinated participants with available reaction data, intent-to-treat population.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Days 0 to 7 post vaccination","groups":[{"id":"OG000","title":"A/H1N1 Vaccine Group 1","description":"Participants who received a dose of 7.5 μg hemagglutinin intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG001","title":"A/H1N1 Vaccine Group 2","description":"Participants who received a dose of 15 μg hemagglutinin intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG002","title":"Placebo Group","description":"Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"106"},{"groupId":"OG002","value":"25"}]}],"classes":[{"title":"Any Solicited Injection Site Reaction - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"16"}]}]},{"title":"Grade 3 Injection Site Reaction - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Pain - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"12"}]}]},{"title":"Any Pain - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"8"}]}]},{"title":"Any Pain - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"16"}]}]},{"title":"Grade 3 Pain (Incapacitating) - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Erythema - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"2"}]}]},{"title":"Any Erythema - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"2"}]}]},{"title":"Any Erythema - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"2"}]}]},{"title":"Grade 3 Erythema (≥ 5 cm) Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Swelling - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"1"}]}]},{"title":"Any Swelling - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Swelling - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"1"}]}]},{"title":"Grade 3 Swelling (≥ 5 cm) Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Induration - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"4"}]}]},{"title":"Any Induration - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Induration - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"4"}]}]},{"title":"Grade 3 Induration (≥ 5 cm) Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Ecchymosis - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"}]}]},{"title":"Any Ecchymosis - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"}]}]},{"title":"Any Ecchymosis - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"2"}]}]},{"title":"Grade 3 Ecchymosis (≥ 5 cm) Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Solicited Systemic Reaction - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"38"},{"groupId":"OG002","value":"12"}]}]},{"title":"Any Grade 3 Solicited Systemic Reaction - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"2"}]}]},{"title":"Any Fever - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}]},{"title":"Any Fever - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"}]}]},{"title":"Any Fever - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"2"}]}]},{"title":"Grade 3 Fever (≥ 102.1 ºF or ≥ 39.0 ºC) - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"}]}]},{"title":"Any Headache - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"5"}]}]},{"title":"Any Headache - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"3"}]}]},{"title":"Any Headache - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"7"}]}]},{"title":"Gr 3 Headache (Prevents daily activity) Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Malaise - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"7"}]}]},{"title":"Any Malaise - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"5"}]}]},{"title":"Any Malaise - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"10"}]}]},{"title":"Gr 3 Malaise (Prevents daily activity) Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"}]}]},{"title":"Any Myalgia - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"}]}]},{"title":"Any Myalgia - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"3"}]}]},{"title":"Any Myalgia - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"3"}]}]},{"title":"Gr 3 Malaise (Prevents daily activity) Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Shivering - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"}]}]},{"title":"Any Shivering - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"}]}]},{"title":"Any Shivering - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"2"}]}]},{"title":"Grade 3 Shivering (Prevents activity) - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Adverse events data were collected from the day of vaccination to up to 6 months post-vaccination.","eventGroups":[{"id":"EG000","title":"A/H1N1 Vaccine Group 1","description":"Participants who received a dose of 7.5 μg hemagglutinin intramuscularly on Day 1 and Day 21, respectively.","seriousNumAffected":1,"seriousNumAtRisk":219,"otherNumAffected":110,"otherNumAtRisk":219},{"id":"EG001","title":"A/H1N1 Vaccine Group 2","description":"Participants who received a dose of 15 μg hemagglutinin intramuscularly on Day 1 and Day 21, respectively.","seriousNumAffected":0,"seriousNumAtRisk":204,"otherNumAffected":104,"otherNumAtRisk":204},{"id":"EG002","title":"Placebo Group","description":"Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively.","seriousNumAffected":1,"seriousNumAtRisk":51,"otherNumAffected":27,"otherNumAtRisk":51}],"seriousEvents":[{"term":"Furuncle","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":51}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":51}]}],"otherEvents":[{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":219},{"groupId":"EG001","numAffected":12,"numAtRisk":204},{"groupId":"EG002","numAffected":1,"numAtRisk":51}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":219},{"groupId":"EG001","numAffected":9,"numAtRisk":204},{"groupId":"EG002","numAffected":6,"numAtRisk":51}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":34,"numAtRisk":219},{"groupId":"EG001","numAffected":22,"numAtRisk":204},{"groupId":"EG002","numAffected":3,"numAtRisk":51}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":219},{"groupId":"EG001","numAffected":22,"numAtRisk":204},{"groupId":"EG002","numAffected":4,"numAtRisk":51}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":80,"numAtRisk":156},{"groupId":"EG001","numAffected":73,"numAtRisk":145},{"groupId":"EG002","numAffected":19,"numAtRisk":33}]},{"term":"Injectiuon site tenderness","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":61},{"groupId":"EG001","numAffected":20,"numAtRisk":55},{"groupId":"EG002","numAffected":10,"numAtRisk":18}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":44,"numAtRisk":217},{"groupId":"EG001","numAffected":34,"numAtRisk":201},{"groupId":"EG002","numAffected":8,"numAtRisk":51}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":217},{"groupId":"EG001","numAffected":21,"numAtRisk":201},{"groupId":"EG002","numAffected":2,"numAtRisk":51}]},{"term":"Injection site induration","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":217},{"groupId":"EG001","numAffected":19,"numAtRisk":201},{"groupId":"EG002","numAffected":6,"numAtRisk":51}]},{"term":"Injection site ecchymosis","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":217},{"groupId":"EG001","numAffected":21,"numAtRisk":201},{"groupId":"EG002","numAffected":4,"numAtRisk":51}]},{"term":"Pyrexia (Fever)","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":217},{"groupId":"EG001","numAffected":14,"numAtRisk":200},{"groupId":"EG002","numAffected":4,"numAtRisk":51}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":156},{"groupId":"EG001","numAffected":21,"numAtRisk":145},{"groupId":"EG002","numAffected":8,"numAtRisk":33}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":39,"numAtRisk":156},{"groupId":"EG001","numAffected":33,"numAtRisk":145},{"groupId":"EG002","numAffected":13,"numAtRisk":33}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":36,"numAtRisk":156},{"groupId":"EG001","numAffected":23,"numAtRisk":145},{"groupId":"EG002","numAffected":5,"numAtRisk":33}]},{"term":"Shivering","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":156},{"groupId":"EG001","numAffected":9,"numAtRisk":145},{"groupId":"EG002","numAffected":2,"numAtRisk":33}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":61},{"groupId":"EG001","numAffected":6,"numAtRisk":55},{"groupId":"EG002","numAffected":0,"numAtRisk":18}]},{"term":"Crying abnormal","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":61},{"groupId":"EG001","numAffected":14,"numAtRisk":55},{"groupId":"EG002","numAffected":7,"numAtRisk":18}]},{"term":"Drowsiness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":61},{"groupId":"EG001","numAffected":11,"numAtRisk":55},{"groupId":"EG002","numAffected":3,"numAtRisk":18}]},{"term":"Appetite lost","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":61},{"groupId":"EG001","numAffected":14,"numAtRisk":55},{"groupId":"EG002","numAffected":4,"numAtRisk":18}]},{"term":"Irritability","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":61},{"groupId":"EG001","numAffected":25,"numAtRisk":55},{"groupId":"EG002","numAffected":9,"numAtRisk":18}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications"},"pointOfContact":{"title":"Medical Director","organization":"Sanofi Pasteur Inc.","email":"RegistryContactUs@sanofipasteur.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D007251","term":"Influenza, Human"}],"ancestors":[{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D007239","term":"Infections"},{"id":"D009976","term":"Orthomyxoviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]}},"hasResults":true}